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Abstract 
Introduction  
Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in 
the United States. Significant clinical disease in COPD patients has been tied to non-
typeable Haemophilus influenzae (NTHI) infection. However, reasons why some NTHI 
strains persist despite antimicrobial therapy remain unknown. 
Objective 
The primary objective was to characterize the pharmacodynamics of azithromycin 
against a persistent pair of NTHI isolates. 
Methods 
A persistent pair of NTHI isolates (5P28H1 and 5P54H1) cultured from the sputum of an 
adult with COPD and determined to be the same strain by multilocus sequence typing 
was carried for 819 days. The Minimum Inhibitory Concentrations (MIC) were 
determined according to Clinical and Laboratory Standards Institute guidelines for 
5P28H1 (MICazithromycin=2.0) and 5P54H1 (MICazithromycin=16.0). Time-kill experiments 
were performed using an array of azithromycin concentrations and samples were 
collected over 48h. The log reduction and integrated log ratio area over 48h were 
calculated and fit to a Hill-type model. A hollow-fiber infection model (HFIM) simulating 
azithromycin concentrations and pharmacokinetics in human serum and alveolar 
macrophages was performed over 240h for 5P28H1. 
Results 
Azithromycin displayed differential killing activity against 5P28H1 and 5P54H1. For 
5P28H1, azithromycin concentrations >0.5 mg/L achieved complete killing by 48h. In 
contrast, complete bacterial killing was observed by 48h for concentrations >4 mg/L in 
5P54H1. Overall, azithromycin demonstrated dose-dependent bactericidal activity 
against both isolates. Pharmacodynamic analysis revealed a right shift in the 
comparative dose response curves. Model fits were excellent (R2>0.99). Azithromycin 
serum concentrations simulated in HFIM did not appreciably reduce 5P28H1 viability by 
240h, whereas simulated alveolar macrophage concentrations achieved complete killing 
by 26hrs.  
Conclusion  
Bactericidal activity was achieved for 5P28H1 at lower concentrations compared to 
5P54H1, which demonstrated an attenuated killing profile. The differential 
pharmacodynamics of azithromycin suggests that antimicrobial pressure plays a role in 
counter selection of resistance for NTHI. 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity 
and mortality worldwide (1, 2). COPD is characterized by irreversible airway obstruction, 
persistent inflammation, and a multitude of comorbidities (2). It is estimated that 24 
million people are affected by COPD in the United States alone, with direct and indirect 
health care costs nearing $50 billion per year (3, 4). In contrast to other leading causes 
of death like cancer and cardiovascular disease, mortality due to COPD appears to be 
on a continuing upward trend (2). While smoking is the primary risk factor, air pollution 
and those exposed to dust, fumes, and chemical vapors comprise a large proportion of 
those developing COPD (2, 5). However, only about 25% of smokers actually develop 
this disease, indicating that other environmental or genetic factors may be involved in its 
pathogenesis (6).  
Recently, it has become clear that bacteria may chronically colonize the lungs of 
COPD patients. Due to host immune responses, persistent bacterial colonization of 
damaged airways may lead to additional inflammation, promoting and advancing 
disease progression. This understanding led to the creation of the “Two-Hit” hypothesis, 
which posits that a combination of environmental and infection-related factors are 
crucial to COPD pathogenesis and progression (6). Apart from chronic bacterial 
colonization, bacterial infections are thought to play a major role in acute exacerbations 
of COPD. Treatment of exacerbations is believed to account for 45%-75% of direct 
COPD-related expenditures (7). These acute exacerbations not only incur significant 
financial costs, but additional social and indirect economic burdens including lost 
wages, absenteeism, and restricted activity (7). 
 It is estimated that approximately 50% of acute exacerbations have bacterial 
etiology (8). The most common species of bacteria isolated from COPD patients’ lungs 
during an acute exacerbation is Haemophilus influenzae (1). H. influenzae exclusively 
infects humans and may cause pneumonia, bacteremia, or meningitis (9). While a 
vaccine exists for one of the six known types of H. influenzae, non-typeable 
(unencapsulated) strains predominate incident infections in the US (9). Thus, non-
typeable H. influenzae (NTHI) is posited to play a significant role in progression of 
impaired pulmonary function observed in COPD patients (10).  
Current guidelines for treating patients with acute COPD exacerbations include 
the prescription of an antibiotic and anti-inflammatory steroid agent (3). Azithromycin, a 
macrolide with both antibiotic and anti-inflammatory properties, is one of the most 
commonly prescribed antimicrobials for exacerbations and is being considered for 
prophylactic use in individuals with moderate-to-severe COPD (11, 12). However, 
treatment and long-term prophylaxis utilizing azithromycin is not a risk-free endeavor. 
Desai and colleagues (2010) noted a clinical association between antibiotic exposure 
and occurrence of resistant pneumococcal strains in a cohort of 127 adult COPD 
patients (8). In this study, it appeared that over 50% of pneumococcal strains obtained 
from patients exposed to macrolides, primarily azithromycin, at some point over a three 
and six month period displayed resistance (8). Additionally, individual and community 
azithromycin usage is known to increase population-level macrolide resistance in 
respiratory pathogens, garnering significant calls for judicious prescription practices 
(12). 
Azithromycin exhibits antimicrobial activity by binding to the 50S ribosome and 
inhibiting protein translation. H. influenzae resistance mechanisms against macrolides 
include ribosomal methylase, intrinsic or acquired efflux pumps, and alterations in 
ribosomal proteins or RNA (13). While the clinical significance of efflux pumps remains 
controversial, strains with mutations in ribosomal proteins L4 or L22 and 23S rRNA tend 
to exhibit higher MICs for azithromycin than wild-type strains and may have significant 
clinical implication (13).  
The pharmacokinetic and pharmacodynamic (PK/PD) profile of azithromycin 
against H. influenzae is crucial to the process of determining clinical susceptibility and 
improving patient outcomes (13). PK refers to the body’s absorption, distribution, 
metabolism, and elimination of an agent (13, 14). Azithromycin is characterized by rapid 
absorption, poor bioavailability when taken orally (~37%), and extensive tissue 
distribution (14, 15). Peak serum concentrations (Cmax) are estimated to be 
approximately 0.4 mg/L, with lung tissue and alveolar macrophage concentrations 
reaching up to 700 times that of serum (14, 15). The body does not metabolize 
azithromycin and excretion occurs through hepatic, transintestinal, and biliary routes 
(14). PD refers to the relationship between antimicrobial agent and pathogen (13). PD 
analysis reveals the effect of antimicrobial drug on killing and micro-organism growth 
dynamics (13). Azithromycin exhibits a concentration-dependent bactericidal effect on 
H. influenzae, in which activity is best determined by the serum concentration-time 
curve (AUC):MIC ratio (14). The AUC is the product of two PK parameters: Cmax and the 
duration of exposure (14). It is important to note that the duration of exposure for 
azithromycin can be quite long, with the terminal half-life estimated to be 68 hours and 
sub-inhibitory concentrations extending for up to 30 days (12, 14, 15).  
The development of macrolide resistance in H. influenzae presents a major 
public health challenge. Since existing literature focuses primarily on pneumococcal 
resistance to macrolide antibiotics, there is a dearth of knowledge on the development 
of resistance in NTHI. Therefore, the underlying conditions allowing resistance to 
develop and optimal therapeutic regimens for treatment of NTHI in the context of COPD 
need delineation. In order to understand the driving factors of NTHI resistance to 
azithromycin, we characterized the pharmacodynamics of azithromycin against a pair of 
clinically persistent, serially obtained NTHI isolates. In addition, we evaluated the drug 
resistance profiles of the clinical isolates by simulating an in-vivo infection utilizing 
clinically relevant azithromycin concentrations and pharmacokinetic parameters.    
 
 
 
 
 
 
 
 
 
 
 
Methods 
Bacterial Strains 
A unique collection of H. influenzae sputum isolates with corresponding whole genome 
sequence, epidemiologic, and clinical data were prospectively collected as part of a 20-
year longitudinal study of COPD infection conducted in Buffalo, NY from 1994-2014 
(16). A pair of clinically persistent, serially obtained non-typeable H. influenzae strains 
from an individual patient in this cohort was obtained. Strains 5P28H1 and 5P54H1 
were isolated from the same patient at clinic visit 28 and 54, respectively, and were 
carried for 819 days (17). Over this time period, the patient experienced 4 courses of 
azithromycin therapy. These strains were of the same multilocus sequence type, with 
5P54H1 harboring a mutation in the L22 ribosomal protein (17). MICs were determined 
according to CLSI guidelines. 5P28H1 exhibited MICazithromycin of 2 mg/L and 5P54H1 
exhibited MICazithromycin of 16 mg/L (17). 
Antibiotic and media 
Azithromycin analytical grade powder was commercially purchased (Sigma Chemical 
Company, St. Louis, MO). Stock solutions of azithromycin in 10% DMSO were prepared 
at the start of each experiment. MIC values for 5P28H1 and 5P54H1 were previously 
determined by broth microdilution in Mueller-Hinton Broth according to CLSI guidelines 
(17). Brain heart infusion (BHI) broth (Difco Laboratories, Detroit, MI) supplemented with 
10 μg/mL NAD and 10 μg/mL Hemin was used for all static time kill experiments. 
Colonies were enumerated on chocolate agar (Thermo Fisher Scientific, Waltham, MA). 
 
 
Static Time Kill Experiments 
Static time kill experiments were performed over 48 hours as previously described, 
using a starting inoculum of 108 CFU/mL (18). In short, fresh bacterial colonies from 
overnight growth were added to BHI broth to create a concentrated suspension. From 
this suspension, 2 mL were removed and diluted with BHI broth and standard 
azithromycin stock solution to achieve a 108 inoculum in a total reaction volume of 20 
mL. Each 20 mL culture was incubated in a 37oC water bath with constant shaking for 
48 hours. At 0, 1, 2, 4, 8, 24, 26, 28, 32, and 48 hours, .1 mL samples were withdrawn 
and serially diluted in sterile saline for CFU/mL enumeration. Colony counts were 
determined by plating 50 μL of each diluted sample onto BHI chocolate agar with an 
automated spiral dispenser (WASP; Don Whitely Scientific Limited, West Yorkshire, 
England) and incubating plates for 24 hours at 35oC with 5% CO2. Time kill experiments 
were performed at azithromycin concentrations chosen as a function of the isolates’ 
MIC: 64, 32, 16, 8, 4, 2, and .5 mg/L. Two growth controls (10% DMSO in BHI and BHI 
only) were run in parallel.  
Pharmacodynamic Modeling 
An integrated PK/PD approach was used to quantify the effect of azithromycin against 
the clinical isolates. The area under the CFU curve (AUCFU) for each azithromycin 
concentration was normalized by the AUCFU in the absence of drug to obtain the log 
ratio area (Equation 1). 
Equation 1: 
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Plots of the log ratio area vs. azithromycin concentration were then constructed, and 
azithromycin’s activity (E) was modeled by the Hill function (Equation 2), where Emax is 
the maximal drug effect, EC50 is the concentration required to obtain half the maximal 
effect, C is the concentration, E0 is the effect in the absence of drug, and H is the 
sigmoidicity constant (version 12, Systat Software Inc., San Jose, CA). Overall model 
fits were analyzed based on coefficients of determination (R2).  
Equation 2: 
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Hollow Fiber Infection Model (HFIM) 
HFIM was used to evaluate how clinically relevant azithromycin regimens affect 
bacterial burden of lung infection over 240 hours (19, 20). The HFIM utilized cellulosic 
cartridge C3008 (FiberCell Systems, Frederick, MD). Essentially, bacteria colonize the 
extracapillary space of the cartridge while nutrients and antibiotic are exchanged 
through hollow fibers. Apart from growth controls for both clinical isolates, azithromycin 
dosing regimens were administered in a two-tiered fashion for 5P28H1 to achieve 
identical areas under concentration-time curve (AUC) as those deemed physiologically 
relevant. We simulated azithromycin pharmacokinetics in both serum and alveolar 
macrophages. A high-burden lung infection was simulated in this model, using a starting 
inoculum of 108 CFU/mL.  
Serum drug concentrations for hollow fiber modeling were determined by 
digitizing data from a 5-day Z-pack pharmacokinetics study in human subjects (21). 
Azithromycin protein binding was estimated to be 51% at .02 mg/L and 7% at 2 mg/L via 
the FDA package insert. We assumed a linear correlation between these two values 
and determined the free amount of azithromycin in plasma accordingly. Azithromycin 
concentrations in alveolar macrophages have been previously determined (15). Using 
Sigma Plot (Systat Software Inc., San Jose, CA), these estimations were used to 
calculate the AUC in order to determine the effective drug concentration for use in HFIM 
over 10 days (shown in Equation 3). 
Equation 3 
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Four models were analyzed: A. 5P28H1 growth control B. 5P54H1 growth 
control C. 5P28H1 + .063 mg/L Azithromycin (AUC-matched serum concentration) D. 
5P28H1 + 80.6 mg/L Azithromycin (AUC-matched alveolar macrophage concentration). 
Samples were serially drawn over 240 hours and plated on chocolate agar. To 
determine shifts in population dynamics, population analyses were performed on all 
models over 240 hours by plating samples on chocolate agar containing 1, 2, 4, 8, and 
16 mg/L azithromycin.  
 
 
 
 
 
 
 
 
Results 
 Static time kill results for 5P28H1 (MICazithromycin: 2 mg/L) are shown in Figure 1. 
By 48 hours, all concentrations of azithromycin above .5 mg/L achieved complete killing 
for isolate 5P28H1. The three highest concentrations of azithromycin (64, 32, and 16 
mg/L) exhibited the most rapid bactericidal effect, completely killing 5P28H1 by 24 
hours. At the only azithromycin concentration tested beneath the MIC of 5P28H1 (.5 
mg/L), minimal killing was observed. The growth controls for 5P28H1 displayed an 
approximate 1-log decrease in CFU/mL by 48 hours. A concentration-dependent effect 
was visible, as decreases in azithromycin concentration led to increased time-to-
complete killing. The bactericidal activity of azithromycin against 5P54H1 (MICazithromycin : 
16 mg/L) is shown in Figure 2. Concentrations of azithromycin at or above the MIC of 
5P54H1 exhibited complete killing by 24 hours. At a concentration of 8 mg/L (half the 
MIC of 5P54H1), azithromycin appeared to effectively eliminate viability by 28 hours. At 
4, 2, and .5 mg/L of azithromycin, initial reductions in viability were essentially nullified 
after 8 hours. 
 To analyze the pharmacodynamic interaction between azithromycin and our two 
strains, we fit a Hill-type function to our time-kill data. The Hill-type function and model 
parameters are displayed in Figure 3. The Hill-model displayed excellent model fits, as 
the R2 values in both sets were greater than .99. The values for Emax and EC50 were 
higher in 5P54H1 (2.38 and 1.47, respectively) than in 5P28H1 (2.25 and .858, 
respectively), indicating azithromycin to be both less efficacious and less potent against 
5P54H1. 
 In order to simulate human infection, we performed HFIM on 5P28H1 and 
5P54H1. The results of the HFIM are displayed in Figure 4. It is evident that both 
5P28H1 and 5P54H1 in the absence of antibiotic were able to grow in the HFIM, 
achieving bacterial densities greater than 109 CFU/mL. While 5P28H1 was previously 
shown to survive in the conditions of the Hollow Fiber cartridge, this was the first test of 
5P54H1 viability in the HFIM. The AUC-matched serum concentration (.063 mg/L) of 
azithromycin was virtually unable to produce any killing effect against 5P28H1. 
However, at a concentration mimicking that within alveolar macrophages (80.6 mg/L), 
5P28H1 exhibited complete loss of viability by 26 hours. A population analysis of 
5P28H1 performed throughout the HFIM did not reveal any significant phenotypic 
changes in antibiotic susceptibility over 10 days (data not shown).  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
To our knowledge, this is one of the first studies examining azithromycin 
pharmacodynamics against resistant NTHI in COPD patients. In this study, we 
elucidated the pharmacodynamics of azithromycin against a pair of clinically persistent 
NTHI isolates. We determined that azithromycin is effective in killing 5P28H1 and 
5P54H1 in a dose-dependent fashion. As the viability of 5P54H1 had not been tested in 
the HFIM previously, we provided proof-of-principle for this isolate to be further 
examined in the model.  
The threat of antibiotic resistance is particularly alarming in the context of COPD. 
It has been shown that alveolar macrophage activity and other bacterial lung defense 
mechanisms are severely inhibited in COPD patients (22-24). Considering that chronic 
bacterial infection may propel lung damage in COPD and that lowered lung defenses of 
COPD patients may foster persistent bacterial colonization, a formidable cycle of 
disease progression exists. COPD patients often rely on both antibiotic and 
corticosteroid treatment to alleviate symptoms. When antibiotic treatments fail, COPD 
patients may experience rapid acceleration of disease and significant social, physical, 
and financial costs. Understanding the pharmacodynamics of azithromycin against 
clinical strains of NTHI may help tailor future treatment regimens and prevent the 
development of macrolide resistance. 
Multiple challenges exist in correlating antimicrobial susceptibilities with clinical 
therapeutic efficacy. Antimicrobial susceptibilities for NTHI, including those for 
azithromycin, are derived utilizing microbiological breakpoints (13). These breakpoints 
are determined based on drug-effect differences between an azithromycin-naïve 
population of H. influenzae (wild-type) and a population exhibiting decreased 
azithromycin activity (13, 25). However, microbiological breakpoints may not correlate 
with clinical outcome and may not be useful for individual case management (13). 
Clinically relevant breakpoints incorporate a number of factors, including: results of 
clinical studies, PK information regarding tissues and fluids, dose-effect relationships, 
and mathematical modeling (13). The possible disconnect between microbiological 
susceptibility breakpoints and clinically relevant breakpoints was evident in our study. 
Isolate 5P28H1, though deemed susceptible to azithromycin through microbiological 
breakpoints, was not cleared by the patient after four courses of azithromycin therapy. 
This disparity may have led to counter-selection and the genetic and phenotypic 
development of azithromycin resistance observed in isolate 5P54H1. Thus, our results 
highlight the need for clinically relevant breakpoints in H. influenzae susceptibility 
testing.  
Our observation regarding the inability of simulated serum concentration 
exposures in the HFIM to kill 5P28H1 yields insight into a less-defined topic in 
azithromycin treatment: utility of serum AUC versus site-specific AUC metrics. It has 
been posited that site-specific azithromycin concentration for lower respiratory tract 
infections is better correlated with antimicrobial effect than serum or systemic measures 
(26, 27). Despite this, site-specific concentrations within the lungs and on epithelial 
surfaces remain poorly understood. Lucchi et al. determined the concentration of 
immediate and extended release azithromycin in epithelial lining fluid (ELF) in patients 
with lung cancer and found values ranging from 0 to 6.81 mg/L (15). In a separate 
study, healthy individuals were administered a single 500 mg dose (comparable to the 
first dose in a Z-pak regimen) and the amount of azithromycin in ELF was undetectable 
(28). Thus, it appears that underlying health conditions as well as individual physiologic 
characteristics may affect the achievable azithromycin concentrations in ELF. To our 
knowledge, no studies have examined the concentration of azithromycin in ELF of 
COPD patients. Additionally, our population analysis of 5P28H1 during the HFIM 
revealed no significant changes in antibiotic susceptibility by day 10. Ultimately, this 
may implicate that multiple regimens of azithromycin were necessary to initiate the 
changes in 5P28H1 to increase its MIC 8-fold.     
Utilizing azithromycin for COPD prophylaxis and treatment of a multitude of 
respiratory diseases could have far reaching consequences. Since commensal bacteria 
are also exposed to azithromycin during treatment, macrolide resistance may develop in 
the microbiota. This process may already be occurring, as multiple studies have found 
macrolide resistance in nasopharyngeal and oropharyngeal isolates after azithromycin 
regimens (12). This may facilitate the transfer of resistance elements between 
commensal and pathogenic bacteria, increasing the population burden of macrolide 
resistance. Azithromycin prescription has also been linked to the development of 
penicillin and multi-drug resistance (12). A Spanish study performed in 2002 found that 
macrolide consumption was more important in driving penicillin resistance than 
consumption of β-lactams (29). Therefore widespread use of azithromycin could drive 
an increase in resistance across drug classes, posing a significant threat to 
antimicrobial stewardship efforts and public health. Thus, broad scale azithromycin 
prescription practices may need reevaluation.  
 While this study sheds light on important issues facing the treatment and 
management of COPD exacerbations using azithromycin, we recognize a few 
limitations to our study. The first limitation is generalizability. The findings from a pair of 
isolates obtained from a single patient in Buffalo, NY may not be generalizable to all 
individuals chronically infected with NTHI. Additionally, we recognize that a broader 
array of physiologically relevant concentrations of azithromycin for time kill experiments 
and the hollow-fiber infection model could have been used. Therefore in future studies 
we hope to utilize a broader array of concentrations with physiological relevance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures  
Figure 1. Static Time Kill results for isolate 5P28H1 (MICazithromycin : 2 mg/L) evaluating 
the bactericidal activity of an array of azithromycin concentrations. 
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Figure 2. Static Time Kill results for 5P54H1 (MICazithromycin : 16 mg/L) evaluating the 
bactericidal activity of an array of azithromycin concentrations. 
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Figure 3. The Hill-type model fit for azithromycin concentrations versus log-ratio area 
for 5P28H1 and 5P54H1. Model parameters, including Emax and EC50 are included with 
percent standard error.  
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Figure 4. HFIM model results over 10-days (240 hours). Viable bacteria as determined 
by CFU/mL are plotted against time. Simulated concentrations of azithromycin in serum 
(.063 mg/L) and alveolar macrophages (80.6 mg/L) were tested against 5P28H1. 
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